Li Siqi, Zeng Zihang, Hong Zixi, Li Jiali, Xie Conghua
Hubei Key Laboratory of Tumor Biological Behaviors, Department of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Discov Oncol. 2025 Jun 16;16(1):1121. doi: 10.1007/s12672-025-02969-3.
Non-small cell lung cancer (NSCLC) patients may exhibit tumor marker expression patterns that do not align with their pathological subtype, yet the clinical significance of these mismatches remains unclear. This study aims to identify novel tumor marker expression patterns and explore their relationship with tumor heterogeneity and progression-free survival (PFS) in NSCLC patients.
Clinical data and serum tumor marker values were collected from 142 patients with stage III-V, unresectable NSCLC in the Zhongnan Hospital of Wuhan University. The Self-organizing map algorithm was used to generate novel tumor marker patterns. We analyzed the association of these patterns with clinicopathological features and prognosis. The in vitro experiment was conducted to evaluate the impact of CA125 on the malignant behavior of squamous cell carcinoma cell lines.
We identified a pattern of low expression of SCC and high expression of CA125 in squamous cell carcinoma patients (HR 2.1704, P = 0.0304), as well as low expression of CEA and high expression of SCC in adenocarcinoma patients (HR 2.3771, P = 0.0235). Both patterns were significant predictors of poor prognosis. Furthermore, squamous cell carcinoma cell lines cultured in a high-CA125 environment exhibited accelerated proliferation in vitro.
NSCLC patients with a pattern of tumor markers mismatched to their pathological type had unfavourable PFS, suggesting a potentially higher degree of tumor heterogeneity.
非小细胞肺癌(NSCLC)患者可能表现出与病理亚型不一致的肿瘤标志物表达模式,然而这些不匹配的临床意义仍不明确。本研究旨在识别新的肿瘤标志物表达模式,并探讨其与NSCLC患者肿瘤异质性和无进展生存期(PFS)的关系。
收集武汉大学中南医院142例Ⅲ-Ⅴ期不可切除NSCLC患者的临床资料和血清肿瘤标志物值。采用自组织映射算法生成新的肿瘤标志物模式。我们分析了这些模式与临床病理特征及预后的相关性。进行体外实验以评估CA125对鳞状细胞癌细胞系恶性行为的影响。
我们在鳞状细胞癌患者中发现了SCC低表达和CA125高表达的模式(HR 2.1704,P = 0.0304),以及腺癌患者中CEA低表达和SCC高表达的模式(HR 2.3771,P = 0.0235)。这两种模式都是预后不良的显著预测因素。此外,在高CA125环境中培养的鳞状细胞癌细胞系在体外表现出增殖加速。
肿瘤标志物模式与病理类型不匹配的NSCLC患者的PFS较差,提示肿瘤异质性可能更高。